“…The early use of immunochemotherapy is beneficial in improving survival, with more than half of HLH patients treated with the HLH-94 regimen achieving 5-year long-term survival, timely immunochemotherapy regimens can rapidly control inflammatory factors and reduce ensuing organ damage [ 31 ]. Our research group has also previously confirmed that decreased TC and elevated BUN are independent risk factors for early death in children with HLH [ 32 ]。Lower cholesterol levels may impair the ability to regulate inflammatory immune responses and neutralize endotoxins in pathological conditions, ultimately leading to a storm of uncontrolled inflammatory factors [ 33 ]. Elevated BUN indicates that patients with HLH may have more severe circulatory perfusion deficits, infections, or acute kidney injury, which increases the risk of death [ 34 , 35 ].…”